← Leaderboards
Hendree E. Jones
Johns Hopkins University
$34,132,831
Attributed
$38,505,657
Total exposure
15
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,505,657 · 15
By mechanism
R01$25,005,926 · 9
N02$11,999,569 · 2
R34$1,115,474 · 2
M01$221,833 · 1
R21$162,855 · 1
Top collaborators
- Karen M Grewen7 shared
- Wei Gao5 shared
- Sarah H Heil5 shared
- John H Gilmore2 shared
- Weili Lin2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Kathryn Jane Spearman$143,591
- Margaret Smith Chisolm$1,925,814
- Namrita Shirin Singh$121,960
- Gretchen Clum$1,230,662
- Tiara C. Willie$5,013,175
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPregnancyBaseReportingWomanOpioidSocialBehavioralPregnant WomenFemaleMethadoneMothersChildHuman Pregnant SubjectNeonatalClinical ResearchDrug UsageBirthHuman Therapy EvaluationNeonatal Abstinence SyndromeBuprenorphineCocaineMedicalProvider
Grant awards (60)
NHLBI CATALYZE PRECLINICAL SERVICES: PROJECTS YR. 4 - TASK ORDER 5$9,999,898
N02 · FY2025 · HL · contact PI
NHLBI CATALYZE COORDINATING CENTER - PRODUCT DEVELOPMENT SUPPORT SERVICES, TASK ORDER 4$1,999,671
N02 · FY2025 · HL · contact PI
Effects of Prenatal Opiates on Infant Brain and Neurobehavioral Development$672,885
R01 · FY2022 · DA
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$649,921
R01 · FY2022 · DA · contact PI
A comprehensive intervention to treat emerging drug-using populations$254,154
R01 · FY2022 · DA · contact PI
Effects of Prenatal Opiates on Infant Brain and Neurobehavioral Development$679,645
R01 · FY2021 · DA
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$652,553
R01 · FY2021 · DA · contact PI
A comprehensive intervention to treat emerging drug-using populations$291,446
R01 · FY2021 · DA · contact PI
Effects of Prenatal Opiates on Infant Brain and Neurobehavioral Development$690,910
R01 · FY2020 · DA
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$658,011
R01 · FY2020 · DA · contact PI
A comprehensive intervention to treat emerging drug-using populations$291,446
R01 · FY2020 · DA · contact PI
Effects of Prenatal Opiates on Infant Brain and Neurobehavioral Development$702,420
R01 · FY2019 · DA
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$661,272
R01 · FY2019 · DA · contact PI
A comprehensive intervention to treat emerging drug-using populations$283,704
R01 · FY2019 · DA · contact PI
1/5, HEAL Consortium: Establishing Innovative Approaches for the HEALthy Brain and Child Development Study$262,407
R34 · FY2019 · DA
1/5, HEAL Consortium: Establishing Innovative Approaches for the HEALthy Brain and Child Development Study$262,406
R34 · FY2019 · DA
Effects of Prenatal Opiates on Infant Brain and Neurobehavioral Development$724,280
R01 · FY2018 · DA
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$709,822
R01 · FY2018 · DA · contact PI
A comprehensive intervention to treat emerging drug-using populations$288,369
R01 · FY2018 · DA · contact PI
Improving Women's Sexual Health While in Drug Addiction Treatment$170,525
R34 · FY2015 · DA · contact PI
HIV and Drug Use in Georgian Women$370,267
R01 · FY2014 · DA · contact PI
Improving Women's Sexual Health While in Drug Addiction Treatment$209,977
R34 · FY2014 · DA · contact PI
HIV and Drug Use in Georgian Women$379,934
R01 · FY2013 · DA · contact PI
Improving Women's Sexual Health While in Drug Addiction Treatment$210,159
R34 · FY2013 · DA · contact PI
HIV and Drug Use in Georgian Women$248,245
R01 · FY2012 · DA · contact PI
HIV and Drug Use in Georgian Women$143,095
R01 · FY2012 · DA · contact PI
HIV and Drug Use in Georgian Women$462,967
R01 · FY2011 · DA · contact PI
Treating South African Pregnant Women for Methamphetamine$162,855
R21 · FY2011 · DA · contact PI
HIV and Drug Use in Georgian Women$430,663
R01 · FY2010 · DA · contact PI
Reinforcement Based Treatment for Pregnant Drug Abusers$523,464
R01 · FY2009 · DA · contact PI
Maternal Opioid Treatment: Human Experimental Research$1,105,489
R01 · FY2008 · DA · contact PI
Tobacco Use in Opioid Agonist treated Pregnant Women$326,848
R01 · FY2008 · DA · contact PI
Maternal Opioid Treatment: Human Experimental Research$40,148
R01 · FY2008 · DA · contact PI
Maternal Opioid Treatment: Human Experimental Research$1,156,470
R01 · FY2007 · DA · contact PI
Treating the Partners of Drug Using Preg Women: Stage II$374,483
R01 · FY2007 · DA · contact PI
Tobacco Use in Opioid Agonist treated Pregnant Women$363,481
R01 · FY2007 · DA · contact PI
Maternal Opioid Treatment: Human Experimental Research$1,165,849
R01 · FY2006 · DA · contact PI
Treating the Partners of Drug Using Preg Women: Stage II$443,535
R01 · FY2006 · DA · contact PI
Recovery Housing for Pregnant Women$372,230
R01 · FY2006 · DA · contact PI
Tobacco Use in Opioid Agonist treated Pregnant Women$364,822
R01 · FY2006 · DA · contact PI
Maternal Opioid Treatment: Human Experimental Research$1,174,280
R01 · FY2005 · DA
Treating the Partners of Drug Using Preg Women: Stage II$505,029
R01 · FY2005 · DA
Recovery Housing for Pregnant Women$408,087
R01 · FY2005 · DA
Tobacco Use in Opioid Agonist treated Pregnant Women$364,138
R01 · FY2005 · DA
Maternal Opioid Treatment: Human Experimental Research$1,205,680
R01 · FY2004 · DA
Treating the Partners of Drug Using Preg Women: Stage II$436,023
R01 · FY2004 · DA
Recovery Housing for Pregnant Women$398,319
R01 · FY2004 · DA
Tobacco Use in Opioid Agonist treated Pregnant Women$355,970
R01 · FY2004 · DA
Methadone &Buprenorphine: Ante- &Post-Partum$221,833
M01 · FY2004 · RR
Treating the Partners of Drug Using Preg Women: Stage II$76,435
R01 · FY2004 · DA
Recovery Housing for Pregnant Women$388,833
R01 · FY2003 · DA
Treating the Partners of Drug Using Preg Women: Stage II$365,904
R01 · FY2003 · DA
BEHAVIORAL THERAPIES FOR DRUG DEPENDENT PREGNANT WOMEN$304,716
R01 · FY2003 · DA
METHADONE AND BUPERNORPHINE: ANTE- AND POST-PARTUM$614,907
R01 · FY2002 · DA
BEHAVIORAL THERAPIES FOR DRUG DEPENDENT PREGNANT WOMEN$369,305
R01 · FY2002 · DA
Recovery Housing for Pregnant Women$348,582
R01 · FY2002 · DA
BEHAVIORAL THERAPIES FOR DRUG DEPENDENT PREGNANT WOMEN$361,286
R01 · FY2001 · DA
TREATING THE PARTNERS OF DRUG USING PREGNANT WOMEN$243,624
R01 · FY2001 · DA
BEHAVIORAL THERAPIES FOR DRUG DEPENDENT PREGNANT WOMEN$353,505
R01 · FY2000 · DA
TREATING THE PARTNERS OF DRUG USING PREGNANT WOMEN$248,475
R01 · FY2000 · DA